{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:08:21Z","timestamp":1772842101209,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,19]],"date-time":"2026-12-19T00:00:00Z","timestamp":1797638400000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI155664"],"award-info":[{"award-number":["R01 AI155664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM129325"],"award-info":[{"award-number":["R01-GM129325"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009768","name":"University of St Thomas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1125975"],"award-info":[{"award-number":["1125975"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bmcl.2025.130505","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:35:22Z","timestamp":1765668922000},"page":"130505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis and evaluation of novel oxanthrene scaffold-derived oxazolidinone antibiotics with potent antitubercular activity and low cellular toxicity"],"prefix":"10.1016","volume":"132","author":[{"given":"Kelsey R.","family":"Latterell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Keil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe B.","family":"Huisken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lillian","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Mel\u00e9ndez","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alejandra Pizarro","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daron E.","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyanu","family":"Lamichhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Thomas","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130505_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2025.130505_bb0010","doi-asserted-by":"crossref","first-page":"21633","DOI":"10.1021\/acs.jmedchem.4c02876","article-title":"Move over COVID, tuberculosis is once again the leading cause of death from a single infectious disease","volume":"67","author":"Berida","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41579-022-00763-4","article-title":"Immune evasion and provocation by mycobacterium tuberculosis","volume":"20","author":"Chandra","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuae006","article-title":"Evolution and emergence of mycobacterium tuberculosis","volume":"48","author":"Orgeur","year":"2024","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.bmcl.2025.130505_bb0025","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2025.130505_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41573-024-00897-5","article-title":"Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease","volume":"23","author":"Dartois","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130505_bb0035","doi-asserted-by":"crossref","first-page":"eado5951","DOI":"10.1126\/sciimmunol.ado5951","article-title":"Immunopathology in human tuberculosis","volume":"9","author":"Scriba","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41579-018-0048-6","article-title":"Multidrug efflux pumps: structure, function and regulation","volume":"16","author":"Du","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0045","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41577-018-0025-3","article-title":"Immunological mechanisms of human resistance to persistent mycobacterium tuberculosis infection","volume":"18","author":"Simmons","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41573-024-00933-4","article-title":"Combating antimicrobial resistance in malaria, HIV and tuberculosis","volume":"23","author":"Duffey","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130505_bb0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bmcl.2025.130505_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2025.130505_bb0070","series-title":"Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update","author":"WHO consolidated guidelines on tuberculosis","year":"2022"},{"key":"10.1016\/j.bmcl.2025.130505_bb0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMra1205429","article-title":"Tuberculosis, drug resistance, and the history of modern medicine","volume":"367","author":"Keshavjee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130505_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5588\/ijtldopen.24.0213","article-title":"Savings from the introduction of BPaL and BPaLM regimens at the country level","volume":"1","author":"Auer","year":"2024","journal-title":"IJTLD OPEN"},{"key":"10.1016\/j.bmcl.2025.130505_bb0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130505_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01655-22","article-title":"Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130505_bb0095","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/pharmaceutics16060818","article-title":"New oxazolidinones for tuberculosis: Are Novel Treatments on the Horizon?","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmcl.2025.130505_bb0100","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1021\/jm800038g","article-title":"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections","volume":"51","author":"Brickner","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0110","series-title":"Antibacterials","first-page":"97","article-title":"The oxazolidinones","author":"Barbachyn","year":"2017"},{"key":"10.1016\/j.bmcl.2025.130505_bb0115","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2024.487","article-title":"Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis","volume":"5","author":"Greenfield","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmcl.2025.130505_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-biochem-062917-011942","article-title":"Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design","volume":"87","author":"Lin","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0130","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1021\/jm800379d","article-title":"Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit","volume":"51","author":"Ippolito","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0135","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1021\/acs.jmedchem.3c01040","article-title":"Strategies for the discovery of oxazolidinone antibacterial agents: development and future perspectives","volume":"66","author":"Liu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/acsptsci.0c00041","article-title":"Characterization of the Core ribosomal binding region for the Oxazolidone family of antibiotics using Cryo-EM","volume":"3","author":"Wright","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmcl.2025.130505_bb0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41594-022-00723-9","article-title":"Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics","volume":"29","author":"Tsai","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf046","article-title":"Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics","volume":"53","author":"Bibel","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2025.130505_bb0155","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41589-019-0423-2","article-title":"Dynamics of the context-specific translation arrest by chloramphenicol and linezolid","volume":"16","author":"Choi","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0160","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1073\/pnas.1613055113","article-title":"Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center","volume":"113","author":"Marks","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2025.130505_bb0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/ph16060784","article-title":"Mechanisms of linezolid resistance in mycobacteria","volume":"16","author":"Gan","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2025.130505_bb0170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025361","article-title":"Bacterial protein synthesis as a target for antibiotic inhibition","volume":"6","author":"Arenz","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bmcl.2025.130505_bb0175","doi-asserted-by":"crossref","first-page":"eadt5833","DOI":"10.1126\/sciadv.adt5833","article-title":"Deciphering linezolid-induced hematologic toxicity: targeting TOP2A and TOP2B via its primary metabolite PNU142586","volume":"11","author":"Thu","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmcl.2025.130505_bb0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejmech.2016.07.001","article-title":"Design, synthesis and biological evaluation of novel azaspiro analogs of linezolid as antibacterial and antitubercular agents","volume":"122","author":"Gadekar","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0185","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","article-title":"Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen","volume":"15","author":"Strydom","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130505_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01542-24","article-title":"Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants","volume":"69","author":"Lombardi","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130505_bb0195","series-title":"Merek Sharp & Dohme LLC, Oxazolidinone Compound and Methods of Use Thereof as an Antibacterial Agent, US Patent US20240208958A1","author":"Crowley","year":"2024"},{"key":"10.1016\/j.bmcl.2025.130505_bb0200","series-title":"Bill & Melinda Gates Medical Research Institute, Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults, ClinicalTrials.gov identifier: NCT05824091","year":"2024"},{"key":"10.1016\/j.bmcl.2025.130505_bb0205","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.bmc.2007.11.040","article-title":"Synthesis of novel oxazolidinone antimicrobial agents","volume":"16","author":"Ebner","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0210","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/anie.200200528","article-title":"Oxazolidinone Structure\u2013Activity Relationships Leading to Linezolid","volume":"42","author":"Barbachyn","year":"2003","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2025.130505_bb0215","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.bmcl.2016.06.019","article-title":"An evolved oxazolidinone with selective potency against mycobacterium tuberculosis and gram positive bacteria","volume":"26","author":"Kaushik","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130505_bb0220","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1021\/acs.jmedchem.0c01177","article-title":"Curse or cure? A perspective on the developability of aldehydes as active pharmaceutical ingredients","volume":"63","author":"Gampe","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0225","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","article-title":"BCG vaccine: WHO position paper, February 2018 \u2013 Recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.bmcl.2025.130505_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1331508","article-title":"Exploring antibiotic resistance mechanisms in mycobacterium abscessus for enhanced therapeutic approaches","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0235","article-title":"Host bioenergetic parameters reveal cytotoxicity of antituberculosis drugs undetected using conventional viability assays","volume":"65","author":"Cumming","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130505_bb0240","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01599-17","article-title":"Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes","volume":"62","author":"Milosevic","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130505_bb0245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/antibiotics12030463","article-title":"Comparative assessment of docking programs for docking and virtual screening of ribosomal oxazolidinone antibacterial agents","volume":"12","author":"Buckley","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.bmcl.2025.130505_bb0250","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41589-023-01525-w","article-title":"Structural basis of Cfr-mediated antimicrobial resistance and mechanisms to evade it","volume":"20","author":"Aleksandrova","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0255","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130505_bb0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1097-2765(02)00570-1","article-title":"The structures of four macrolide antibiotics bound to the large ribosomal subunit","volume":"10","author":"Hansen","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmcl.2025.130505_bb0265","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2533\/chimia.2025.152","article-title":"Reversible covalent reactions of aldehydes and Salicylaldehydes using a lysine-model substrate","volume":"79","author":"Delmas","year":"2025","journal-title":"Chimia"},{"key":"10.1016\/j.bmcl.2025.130505_bb0270","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"Van De Waterbeemd","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130505_bb0275","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2025.130505_bb0280","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/DDDT.S136335","article-title":"Evaluation of the stability of linezolid in aqueous solution and commonly used intravenous fluids","volume":"11","author":"Taylor","year":"2017","journal-title":"DDDT"},{"key":"10.1016\/j.bmcl.2025.130505_bb0285","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1586\/14787210.6.6.825","article-title":"Linezolid for the treatment of drug-resistant infections","volume":"6","author":"Herrmann","year":"2008","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.bmcl.2025.130505_bb0290","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2025.130505_bb0295","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1021\/acsinfecdis.4c00025","article-title":"Mtb-selective 5-Aminomethyl oxazolidinone prodrugs: robust potency and potential liabilities","volume":"10","author":"Boshoff","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130505_bb0300","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1021\/acsmedchemlett.4c00114","article-title":"Design and synthesis of the linezolid bioisosteres to resolve the serotonergic toxicity associated with linezolid","volume":"15","author":"Girase","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130505_bb0305","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/acs.joc.1c01431","article-title":"Metal-free, rapid, and highly Chemoselective reduction of aromatic nitro compounds at room temperature","volume":"87","author":"Jang","year":"2022","journal-title":"J Organomet Chem"},{"key":"10.1016\/j.bmcl.2025.130505_bb0310","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/op034028h","article-title":"The synthesis of N -Aryl-5(S)-aminomethyl-2-oxazolidinone Antibacterials and derivatives in one step from aryl carbamates","volume":"7","author":"Perrault","year":"2003","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmcl.2025.130505_bb0315","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/am.26.5.658-665.1973","article-title":"Microdilution antibiotic susceptibility test: examination of certain variables","volume":"26","author":"Tilton","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0320","series-title":"Some Common Methods in Mycobacterial Genetics, in: Hatfull GF Jacobs W R J Ed. Mol Genet Mycobact","first-page":"313","author":"Larsen","year":"2000"},{"key":"10.1016\/j.bmcl.2025.130505_bb0325","series-title":"Clin. Lab. Stand. Inst., CLSI, Wayne, PA, USA","first-page":"M100","article-title":"Performance standards for antimicrobial susceptibility testing: Fifteenth informational supplement","year":"2005"},{"key":"10.1016\/j.bmcl.2025.130505_bb0330","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/acsinfecdis.7b00028","article-title":"Ribosome rescue inhibitors kill actively growing and nonreplicating Persister mycobacterium tuberculosis cells","volume":"3","author":"Alumasa","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2025.130505_bb0335","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fmicb.2017.02204","article-title":"Reporter-based assays for high-throughput drug screening against mycobacterium abscessus","volume":"8","author":"Gupta","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2025.130505_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2021.102062","article-title":"HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during mycobacterium tuberculosis infection","volume":"127","author":"Campo","year":"2021","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bmcl.2025.130505_bb0345","series-title":"Rigaku Americas and Rigaku, CrystalClear","year":"2011"},{"key":"10.1016\/j.bmcl.2025.130505_bb0350","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1107\/S002188980403225X","article-title":"SIR2004: an improved tool for crystal structure determination and refinement","volume":"38","author":"Burla","year":"2005","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmcl.2025.130505_bb0355","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1107\/S1600576713027659","article-title":"Refinement of macromolecular structures against neutron data with SHELXL2013","volume":"47","author":"Gruene","year":"2014","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmcl.2025.130505_bb0360","series-title":"Bruker, APEX4","year":"2021"},{"key":"10.1016\/j.bmcl.2025.130505_bb0365","volume":"2018","year":"2013","journal-title":"SHELXTL"},{"key":"10.1016\/j.bmcl.2025.130505_bb0370","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr A"},{"key":"10.1016\/j.bmcl.2025.130505_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:00:41Z","timestamp":1769835641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":75,"alternative-id":["S0960894X25004147"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130505","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-rkphb","asserted-by":"object"}]},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of novel oxanthrene scaffold-derived oxazolidinone antibiotics with potent antitubercular activity and low cellular toxicity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130505"}}